ClinicalTrials.gg
Active, not recruitingNCT04194944LIBRETTO-431Updated Oct 21, 2026Results posted

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

A Phase 3 interventional study of Selpercatinib and Carboplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 196 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Posted results revised2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.

Enrollment
29th of 139
261 · median 109
Started
2020
with 2 others
Phase 3
25 of 147
2 open now
Primary completion
2023-05
later than 4 of 19 live
Registered
131st of 147
by date

Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 29th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2020, is one of 25 in phase 3, reaches primary completion later than 4 of the 19 other live ones, and was the 131st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • targeted therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed, Stage IIIB-IIIC or Stage IV non-squamous NSCLC that is not suitable for radical surgery or radiation therapy.
  • A RET gene fusion in tumor and/or blood from a qualified laboratory.
  • (ECOG) performance status of 0-2.
  • Adequate hematologic, hepatic and renal function.
  • Willingness of men and women of to observe conventional and highly effective for the duration of treatment and for 6 months after.
  • Ability to swallow capsules.

Exclusion criteria

Exclusion Criteria:

  • Additional validated oncogenic drivers in NSCLC if known.
  • Prior systemic therapy for disease. Treatment (chemotherapy, immunotherapy, or biological therapy) in the /neoadjuvant setting is permitted if it was completed at least 6 months prior to randomization.
  • Major surgery within 3 weeks prior to planned start of selpercatinib.
  • Radiotherapy for palliation within 1 week of the first dose of study treatment or any radiotherapy within 6 months prior to the first dose of study treatment if more than 30 Gy to the lung.
  • Symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or untreated spinal cord compression.
  • active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of selpercatinib or prolongation of the corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds.
  • Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment.
  • Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
  • Pregnancy or lactation.
  • Other unless nonmelanoma skin cancer, carcinoma in situ of the cervix or other in situ cancers or a malignancy diagnosed ≥2 years previously and not currently active.
  • Uncontrolled, disease related pericardial effusion or pleural effusion.
  • Requiring chronic treatment with .

Exclusion Criteria for Participants Receiving Pembrolizumab:

  • History of interstitial lung disease or interstitial pneumonitis.
  • Active disease or any illness or treatment that could compromise the immune system.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    Selpercatinib - Treatment A (TRT A)

    160 milligram (mg) Selpercatinib administered orally twice daily (BID) continuously in 21-day cycles.

    Drug: Selpercatinib

  • Active comparator
    Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)

    Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.

    Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)

    PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.

    Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months

  2. PFS by BICR (With or Without Pembrolizumab)

    PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.

    Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months

Secondary outcomes

  1. Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)

    DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.

    Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months

  2. Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)

    DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.

    Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months

  3. PFS2 (With Pembrolizumab)

    PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.

    Time frame: Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months

  4. PFS2 (With or Without Pembrolizumab)

    PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.

    Time frame: Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months

  5. Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)

    ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.

    Time frame: Baseline through Disease Progression or Death Up to 31 Months

  6. ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)

    ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.

    Time frame: Baseline through Disease Progression or Death Up to 31 Months

  7. Duration of Response (DoR) by BICR (With Pembrolizumab)

    DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months

  8. DOR by BICR (With or Without Pembrolizumab)

    DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months

  9. Overall Survival (OS) (With Pembrolizumab)

    Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data was censored on the last date the participant is known to be alive.

    Time frame: Baseline to Date of Death from Any Cause Up to 38 Months

  10. OS (With or Without Pembrolizumab)

    Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.

    Time frame: Baseline to Date of Death from Any Cause Up to 38 Months

  11. Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)

    Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with Pembrolizumab)

    Time frame: Baseline through Central Nervous System (CNS) Progression or Death up to 31 Months

  12. Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

    Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)

    Time frame: Baseline through CNS Progression or Death Up to 31 Months

  13. Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)

    Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)

    Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

  14. Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

    Median Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)

    Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

  15. Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)

    Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)

    Time frame: Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months

  16. Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)

    Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-SAQ (with or without Pembrolizumab)

    Time frame: Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months

  17. The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)

    The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)

    Time frame: Baseline

  18. Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)

    Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)

    Time frame: Baseline through CNS Progression or Death Up to 31 Months

  19. Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

    Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)

    Time frame: Baseline through CNS Progression or Death Up to 31 Months

  20. Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (With Pembrolizumab)

    Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with Pembrolizumab)

    Time frame: Baseline through CNS Progression or Death Up to 31 Months

  21. Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RANO-BM by BICR (With or Without Pembrolizumab)

    Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)

    Time frame: Baseline through CNS Progression or Death Up to 31 Months

  22. Intracranial DOR Per RANO-BM by BICR (With Pembrolizumab)

    Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)

    Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

  23. Intracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)

    Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)

    Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

07

Results

Posted Jun 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Started159102
Received at least one dose of study drug15898
Completed6170
Not completed9832
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject22
Withdrew: On treatment9330

Outcome measures

PrimaryProgression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)

PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.

Time frame:
Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Reported as:
Median · Months
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)24.84 (16.89 to NA)11.17 (8.77 to 16.76)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With Pembrolizumab (TRT B) · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.465 · 95% CI 0.309 to 0.699
PrimaryPFS by BICR (With or Without Pembrolizumab)

PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.

Time frame:
Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Reported as:
Median · Months
PFS by BICR (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
PFS by BICR (With or Without Pembrolizumab)24.84 (17.31 to NA)11.17 (8.77 to 16.76)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.482 · 95% CI 0.331 to 0.700
SecondaryPercentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)

DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.

Time frame:
Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Reported as:
Number · Percentage of Participants
Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)
Percentage of ParticipantsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)89.1 (82.5 to 93.9)84.3 (74.7 to 91.4)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.3996 · Odds ratio (or): 1.5 · 95% CI 0.7 to 3.4
SecondaryPercentage of Participant With DCR by BICR (With or Without Pembrolizumab)

DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.

Time frame:
Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Reported as:
Number · Percentage of Participants
Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)
Percentage of ParticipantsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)89.3 (83.4 to 93.7)82.4 (73.6 to 89.2)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.1390 · Odds ratio (or): 1.7 · 95% CI 0.9 to 3.6
SecondaryPFS2 (With Pembrolizumab)

PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.

Time frame:
Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months
Reported as:
Median · Months
PFS2 (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
PFS2 (With Pembrolizumab)NA (NA to NA)NA (NA to NA)
SecondaryPFS2 (With or Without Pembrolizumab)

PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.

Time frame:
Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months
Reported as:
Median · Months
PFS2 (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
PFS2 (With or Without Pembrolizumab)NA (NA to NA)NA (NA to NA)
SecondaryOverall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)

ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.

Time frame:
Baseline through Disease Progression or Death Up to 31 Months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)
Percentage of participantsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)83.7 (76.2 to 89.6)65.1 (53.8 to 75.2)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.0028 · Odds ratio (or): 2.7 · 95% CI 1.4 to 5.1
SecondaryORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)

ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.

Time frame:
Baseline through Disease Progression or Death Up to 31 Months
Reported as:
Number · Percentage of Participants
ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)
Percentage of ParticipantsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)83.6 (77.0 to 89.0)62.7 (52.6 to 72.1)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.0003 · Odds ratio (or): 2.9 · 95% CI 1.6 to 5.2
SecondaryDuration of Response (DoR) by BICR (With Pembrolizumab)

DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.

Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months
Reported as:
Median · Months
Duration of Response (DoR) by BICR (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Duration of Response (DoR) by BICR (With Pembrolizumab)24.18 (17.94 to NA)11.47 (9.66 to 23.26)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With Pembrolizumab (TRT B) · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.377 · 95% CI 0.224 to 0.633
SecondaryDOR by BICR (With or Without Pembrolizumab)

DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.

Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months
Reported as:
Median · Months
DOR by BICR (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
DOR by BICR (With or Without Pembrolizumab)24.18 (17.94 to NA)11.99 (9.69 to 23.26)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.418 · 95% CI 0.256 to 0.684
SecondaryOverall Survival (OS) (With Pembrolizumab)

Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data was censored on the last date the participant is known to be alive.

Time frame:
Baseline to Date of Death from Any Cause Up to 38 Months
Reported as:
Median · Months
Overall Survival (OS) (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Overall Survival (OS) (With Pembrolizumab)NA (NA to NA)NA (NA to NA)
SecondaryOS (With or Without Pembrolizumab)

Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.

Time frame:
Baseline to Date of Death from Any Cause Up to 38 Months
Reported as:
Median · Months
OS (With or Without Pembrolizumab)
MonthsSelpercatinibPemetrexed and Platinum With or Without Pembrolizumab
OS (With or Without Pembrolizumab)33.05 (33.05 to NA)NA (NA to NA)
SecondaryIntracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)

Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with Pembrolizumab)

Time frame:
Baseline through Central Nervous System (CNS) Progression or Death up to 31 Months
Reported as:
Number · Percentage of participants
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)
Percentage of participantsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)81 (58.1 to 94.6)57.1 (34.0 to 78.2)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.1809 · Odds ratio (or): 3.2 · 95% CI 0.8 to 12.8
SecondaryIntracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)

Time frame:
Baseline through CNS Progression or Death Up to 31 Months
Reported as:
Number · Percentage of participants
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
Percentage of participantsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)84.0 (63.9 to 95.5)50.0 (29.9 to 70.1)
Statistical analysis
  • Selpercatinib (TRT A) vs Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) · Cochran-Mantel-Haenszel · p = 0.0167 · Odds ratio (or): 5.2 · 95% CI 1.4 to 19.6
SecondaryMedian Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)

Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)

Time frame:
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
Reported as:
Median · Months
Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)NA (14.75 to NA)NA (8.74 to NA)
SecondaryMedian Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

Median Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)

Time frame:
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
Reported as:
Median · Months
Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)NA (9.53 to NA)13.40 (4.17 to NA)
SecondaryTime to Deterioration of Pulmonary Symptoms (With Pembrolizumab)

Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)

Time frame:
Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months
Reported as:
Median · Months
Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)NA (NA to NA)1.9 (0.7 to 6.6)
SecondaryTime to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)

Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-SAQ (with or without Pembrolizumab)

Time frame:
Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months
Reported as:
Median · Months
Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)NA (NA to NA)1.6 (0.7 to 4.9)
SecondaryThe Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)

The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)

Time frame:
Baseline

Results for this outcome have not been posted.

SecondaryMedian Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)

Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)

Time frame:
Baseline through CNS Progression or Death Up to 31 Months
Reported as:
Median · Months
Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With Pembrolizumab (TRT B)
Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)NA (NA to NA)NA (NA to NA)
SecondaryMedian Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)

Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)

Time frame:
Baseline through CNS Progression or Death Up to 31 Months
Reported as:
Median · Months
Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
MonthsSelpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)
Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)NA (NA to NA)NA (NA to NA)
SecondaryIntracranial ORR: Percentage of Participants With Intracranial CR or PR Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (With Pembrolizumab)

Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with Pembrolizumab)

Time frame:
Baseline through CNS Progression or Death Up to 31 Months

Results for this outcome have not been posted.

SecondaryIntracranial ORR: Percentage of Participants With Intracranial CR or PR Per RANO-BM by BICR (With or Without Pembrolizumab)

Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)

Time frame:
Baseline through CNS Progression or Death Up to 31 Months

Results for this outcome have not been posted.

SecondaryIntracranial DOR Per RANO-BM by BICR (With Pembrolizumab)

Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)

Time frame:
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

Results for this outcome have not been posted.

SecondaryIntracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)

Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)

Time frame:
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

Results for this outcome have not been posted.

Adverse events

Collected over Baseline Up to 38 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selpercatinib (TRT A)32/158 (20.3%)55/158 (34.8%)156/158 (98.7%)
Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B)17/98 (17.3%)23/98 (23.5%)97/98 (99%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventSelpercatinib (TRT A)Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B)
Pleural effusionRespiratory, thoracic and mediastinal disorders7/1580/98
Hepatic function abnormalHepatobiliary disorders4/1580/98
AnaemiaBlood and lymphatic system disorders0/1582/98
NeutropeniaBlood and lymphatic system disorders0/1582/98
Intestinal obstructionGastrointestinal disorders1/1582/98
PyrexiaGeneral disorders2/1582/98
PneumoniaInfections and infestations3/1582/98
Platelet count decreasedInvestigations1/1582/98
Spinal cord compressionNervous system disorders0/1582/98
AscitesGastrointestinal disorders3/1580/98
Most frequent other events
Showing 10 of 77
Most frequent other events
EventSelpercatinib (TRT A)Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B)
Aspartate aminotransferase increasedInvestigations97/15839/98
Alanine aminotransferase increasedInvestigations95/15839/98
AnaemiaBlood and lymphatic system disorders18/15857/98
HypertensionVascular disorders76/1587/98
NauseaGastrointestinal disorders20/15843/98
DiarrhoeaGastrointestinal disorders69/15824/98
ConstipationGastrointestinal disorders34/15839/98
Dry mouthGastrointestinal disorders61/1586/98
Blood bilirubin increasedInvestigations59/1581/98
Decreased appetiteMetabolism and nutrition disorders27/15833/98

Baseline characteristics

Intent to Treat Population (ITT): All randomized participants, even if a participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

Age, Continuous
Age, Continuous(years)Selpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)Total
Mean60.2 ± 11.360.8 ± 11.460.4 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Selpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)Total
Female8657143
Male7345118
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)Total
American Indian or Alaska Native213
Asian9252144
Native Hawaiian or Other Pacific Islander000
Black or African American202
White5843101
More than one race101
Unknown or Not Reported4610
Region of Enrollment
Region of Enrollment(Participants)Selpercatinib (TRT A)Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)Total
Hong Kong415
Czechia011
Russia123
Greece202
Netherlands213
South Korea8816
China622890
Brazil718
Poland011
France246
Argentina202
Japan151025
Ukraine055
Spain7916
Canada213
Turkey808
Belgium336
Taiwan246
Italy201232
Mexico415
Israel145
Australia224
Germany549
08

Study locations

196 sites

Showing the first 100 of 196 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Duke ES, Bradford D, Sinha AK, Li X, Mishra-Kalyani PS, de Claro RA, Larkins E, Drezner N. Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. J Clin Oncol. 2026 May 20;44(15):1457-1464. doi: 10.1200/JCO-25-02375. Epub 2026 Apr 17. PubMed 41996652 ↗
  • Perol M, Solomon BJ, Goto K, Park K, Nadal E, Bria E, Martin C, Bar J, Williams JN, Puri T, Li J, Uh MK, Lin BK, Zhou C. CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer. J Clin Oncol. 2024 Jul 20;42(21):2500-2505. doi: 10.1200/JCO.24.00724. Epub 2024 Jun 3. PubMed 38828957 ↗
  • Zhou C, Solomon B, Loong HH, Park K, Perol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. PubMed 37870973 ↗
  • Claerhout S, Lehnert S, Vander Borght S, Spans L, Dooms C, Wauters E, Vansteenkiste J, Weynand B, Deraedt K, Bourgain C, Vanden Bempt I. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer. Lung Cancer. 2022 Apr;166:242-249. doi: 10.1016/j.lungcan.2022.02.013. Epub 2022 Mar 1. PubMed 35378489 ↗
  • Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Perol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5. PubMed 33150799 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in May 2023, 38 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Dec 11, 2019
StartActual
Feb 17, 2020
Primary completionActual
May 1, 2023
CompletionEst.
Jun 2030
Results first posted
Jun 20, 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 21, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Turkey (Türkiye))
  • Baskent University Dr. Turgut Noyan Research and Training Center · Adana, Turkey (Türkiye)
  • Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital · Ankara, Turkey (Türkiye)
Show 2 removed
  • Baskent University Dr. Turgut Noyan Research and Training Center · Adana, Turkey (Türkiye)
  • Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital · Ankara, Turkey (Türkiye)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Posted results revised
    2 sites added, 2 sites removed
    Show 2 added (2 Turkey (Türkiye))
    • Baskent University Dr. Turgut Noyan Research and Training Center · Adana, Turkey (Türkiye)
    • Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital · Ankara, Turkey (Türkiye)
    Show 2 removed
    • Baskent University Dr. Turgut Noyan Research and Training Center · Adana, Turkey (Türkiye)
    • Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital · Ankara, Turkey (Türkiye)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04194944
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 11, 2019
Start date
Feb 17, 2020
Primary completion
May 1, 2023
Completion
Jun 2030 (estimated)
Results posted
Jun 20, 2024
Last update
Oct 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion